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identification of suggestive sex-differential risk loci
for autism spectrum disorder
Donna M Werling1, Jennifer K Lowe2,3,4, Rui Luo2,5, Rita M Cantor4,5 and Daniel H Geschwind2,3,4,5*Abstract
Background: Autism spectrum disorders (ASDs) are male-biased and genetically heterogeneous. While sequencing
of sporadic cases has identified de novo risk variants, the heritable genetic contribution and mechanisms driving the
male bias are less understood. Here, we aimed to identify familial and sex-differential risk loci in the largest available,
uniformly ascertained, densely genotyped sample of multiplex ASD families from the Autism Genetics Resource
Exchange (AGRE), and to compare results with earlier findings from AGRE.
Methods: From a total sample of 1,008 multiplex families, we performed genome-wide, non-parametric linkage
analysis in a discovery sample of 847 families, and separately on subsets of families with only male, affected children
(male-only, MO) or with at least one female, affected child (female-containing, FC). Loci showing evidence for
suggestive linkage (logarithm of odds ≥2.2) in this discovery sample, or in previous AGRE samples, were re-evaluated in
an extension study utilizing all 1,008 available families. For regions with genome-wide significant linkage signal
in the discovery stage, those families not included in the corresponding discovery sample were then evaluated
for independent replication of linkage. Association testing of common single nucleotide polymorphisms (SNPs)
was also performed within suggestive linkage regions.
Results: We observed an independent replication of previously observed linkage at chromosome 20p13 (P < 0.01),
while loci at 6q27 and 8q13.2 showed suggestive linkage in our extended sample. Suggestive sex-differential linkage
was observed at 1p31.3 (MO), 8p21.2 (FC), and 8p12 (FC) in our discovery sample, and the MO signal at 1p31.3 was
supported in our expanded sample. No sex-differential signals met replication criteria, and no common SNPs were
significantly associated with ASD within any identified linkage regions.
Conclusions: With few exceptions, analyses of subsets of families from the AGRE cohort identify different risk loci,
consistent with extreme locus heterogeneity in ASD. Large samples appear to yield more consistent results, and
sex-stratified analyses facilitate the identification of sex-differential risk loci, suggesting that linkage analyses in
large cohorts are useful for identifying heritable risk loci. Additional work, such as targeted re-sequencing, is
needed to identify the specific variants within these loci that are responsible for increasing ASD risk.
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Autism spectrum disorders (ASDs) are a group of neuro-
developmental conditions characterized by severe social
impairment that affect 1 in 88 individuals [1]. Genetic
factors have long been known to contribute significantly
to ASD risk based on twin studies [2], the sibling recur-
rence risk [3,4], and elevated rates of comorbid ASD in
populations with a wide variety of monogenic syndromes
such as Fragile X or Timothy Syndrome [5,6]. ASDs are
also known to present heterogeneously across the popula-
tion of affected individuals, and results from recent
genetic studies strongly suggest that genetic risk factors
for ASD are similarly diverse. Copy number variant (CNV)
and exome sequencing studies of sporadic ASD cases from
single-incidence (“simplex”) families have found numerous
novel, de novo risk variants [7-13], and no significant signal
for rare inherited variation. Estimates based on these
findings project that approximately 1,000 genes are likely
to contribute to ASD etiology.
While a highly productive approach for gene discovery,
the study of simplex families is designed to identify mostly
the non-inherited genetic component of ASD risk: rare
variants resulting from de novo mutations, in which
variants arise in the germ cell and are not carried by the
mother or father. However, evidence of high heritability
for ASD [14], high sibling recurrence risk [3,4], and aggre-
gation of subthreshold ASD-like phenotypes in families
[15-18] suggest that inherited genetic variation also plays
a significant role in ASD etiology.
Additionally, while germline mutations, potentially shared
between affected siblings, may also plausibly affect ASD risk
in multiplex families, current evidence suggests that rare de
novo CNV events are more prevalent among sporadic cases
than cases from multiple-incidence (“multiplex”) families
[13]. Largely, however, the specifics of the genetic archi-
tecture of ASDs that differ between simplex and multiplex
families are unknown. Therefore, studies of familial trans-
mission to identify regions of genetic linkage in multiplex
families remain an important approach to identifying
predisposing genes.
Another important clue to ASD etiology lies in its
consistently male-biased prevalence [19]. There is an
approximately 4:1 male bias, a phenomenon that is likely
driven, or at least influenced, by the actions of sex-specific
biological factors, such as sex chromosomes or steroid
hormones that potentiate and attenuate ASD risk in males
and females, respectively [20]. Indeed, several ASD and
intellectual disability risk genes have been identified on
the X chromosome [6,21], including FMR1 [22], NLGN4X,
and NLGN3 [23], demonstrating that in some cases ASD
may be X-linked. However, the proportion of ASD cases
currently attributable to X-linked variants remains insuffi-
cient to account for the degree of male bias observed in
ASD prevalence. The notion of female protective factorson a broader scale is supported by the observation of an
increased proportion of autistic females relative to males
carrying variants of large effect size, such as large CNVs
or deleterious single nucleotide variants (SNVs) [8,11,13].
However, with few exceptions [24], it is unknown which
specific autosomal risk variants are differentially penetrant
by sex, thus contributing to the sex bias in ASD prevalence.
For example, a greater number of variants may be associ-
ated with ASD risk in males as compared to the number of
variants that also, or specifically, confer risk to females. The
discovery of such sex-differential risk loci would provide
genetic clues for investigation of the biological mechanisms
driving the ASD male bias. However, because these signals
are likely masked by heterogeneity within sex-mixed
cohorts, stratification of multiplex ASD family cohorts by
proband sex may facilitate the identification of novel,
sex-differential loci harboring inherited risk variants.
Most previous linkage studies of ASD have used relatively
small samples (<350 families) and markers with coarse
resolution and incomplete information [25-31], and there
has been little agreement between studies in the reported
findings. Furthermore, the larger studies [32,33] combine
subjects drawn from several diverse populations with
different ascertainment schemes. Multiplex family samples
ranging from 109 to 753 families from the Autism Genetics
Resource Exchange (AGRE) cohort have been previously
tested for linkage [25-28,33,34], and the linked risk loci re-
ported by these analyses, with a few exceptions [25,28],
show little agreement. This may be due to genetic hetero-
geneity, small sample sizes, or sparse marker coverage.
In this study, we used a pruned set of single nucleotide
polymorphism (SNP) markers providing nearly complete
linkage information on all autosomes and the X chromo-
some (information content greater than 0.976 for 99.5%
of regions covered by SNP genotypes) for our analyses
in the largest available AGRE sample. Specifically, we
performed non-parametric linkage testing in three stages
to: 1) identify novel risk loci in a discovery sample of 847
multiplex families; 2) confirm loci identified in this dis-
covery sample, or reported by earlier analyses of AGRE
samples, in an extended sample of 1,008 multiplex families;
and 3) test for formal replication of genome-wide sig-
nificant linkage signals in the independent portion of
families not tested in the corresponding discovery studies
(Figure 1).
For all stages, we also applied a stratification approach
used previously [25,28,32] to identify sex-differential loci,
now using a sample three times as large as the original and
a panel of markers that are substantially more informative
[28]. We then used the family-based association transmis-
sion disequilibrium test (TDT) on genotyped and imputed
SNPs within linked regions to identify common variants
conferring increased risk for ASD. With the addition of 343
AGRE families beyond those tested in the most recent
1a) Stage 1 discovery study 
• Genome-wide linkage analysis
• 847 multiplex families from AGRE
• SNP genotypes from Illumina 550K & Omni-1
1b) Linkage signals in 
samples including AGRE 
* Genome-wide significant linkage 
Source Subgrp Locus Peak 
LOD 
Liu et al. (2001) ALL 5p13.1 2.55 
ALL Xq26.1 2.56 
Yonan et al. (2003) ALL 5p13.1 2.54 
ALL 11p13-11.2 2.24 
ALL 17q11.2 2.83 
Stone et al. (2004) MO 17q11 4.3* 
FC 4q32.3-35.1 2.7 
Cantor et al. (2005) MO 17q21 3.6* 
McCauley et al. 
(2005) 
ALL 3p25.3 2.22 
Szatmari et al. 
(2007) 
MO 5q12 2.31 
MO 9q33.3 2.36 
ALL 11p12 2.77 
FC 11p12 2.86 
Weiss et al. (2009) ALL 6q27 2.94 
ALL 20p13 3.81* 
2) Combined 
stage extension 
study 
• Regional linkage
analysis in loci with
suggestive LOD
scores
• 1008 multiplex
families from AGRE
• SNP genotypes from
Illumina Omni-1 &
Omni-2.5
3) Replication 
study 
• Regional linkage
analysis in loci with
genome-wide
significant LOD
scores (LOD>3.6)
• Multiplex families
from AGRE not
tested in the
corresponding
discovery sample
Figure 1 Schematic of three-stage study design for linkage analyses. Linkage analyses were performed using a three-stage approach.
(1a) A discovery sample (Stage 1) and (1b) previous linkage results were used to identify loci of suggestive linkage (logarithm of odds (LOD) ≥2.2).
(2) These suggestive loci were tested for linkage in an extended sample. (3) For loci achieving genome-wide significant linkage (LOD ≥3.6) in either
the discovery, extended, or previously published studies, the non-overlapping subset of families was tested for independent replication of linkage.
AGRE, Autism Genetics Resource Exchange; SNP, single nucleotide polymorphism.
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prises the largest linkage study for ASD, and sex-differential
risk, of families from a single, uniformly ascertained cohort.
This also allows us to attempt replication of previous
linkage findings.
Methods
Subjects and genotyping
Subjects were individuals from the AGRE collection
of nuclear families, including affected probands, their
unaffected siblings, and their parents. Subjects provided
written informed consent or, if minors, assent with agree-
ment from their parents to AGRE for diagnosis and
blood collection. This study was approved by the Western
Institutional Review Board (AGRE), the Institutional
Review Board at Washington University (subject recruit-
ment, principal investigator: John Constantino), and by
the Medical Institutional Review Board 3 at the University
of California, Los Angeles.
Individuals with study diagnoses of full autism, not quite
autism, or broad spectrum disorder based on a clinician’s
best estimate given Autism Diagnostic Interview-Revised
and Autism Diagnosis Observation Schedule scores were
considered to be affected, in accordance with the inclusive,
single spectrum concept of ASD as now codified in the
Diagnostic and Statistical Manual-5. In the AGRE cohort,
a study diagnosis of not quite autism is given to subjects
who meet the age of onset criterion but score no more
than one point short of the autism cutoffs in one or more
symptom domains (social, communication, restricted andrepetitive behavior), or subjects who meet autism cutoffs
in all symptom domains, but do not meet the age of onset
criterion. A study diagnosis of broad spectrum disorder is
given to subjects with pervasive developmental disorders
and varying levels of impairment; these subjects include
individuals with conditions like pervasive developmental
disorder not otherwise specified (PDD-NOS) and Asperger’s
syndrome.
Probands with syndromic autism, significant dysmor-
phology, documented pre- or peri-natal insult, abnormal
imaging or medical test, premature birth at less than 35
gestational weeks, or chromosomal abnormalities were
not included; additional neuropsychiatric phenotypes in
parents and unaffected siblings were not applied as inclu-
sion or exclusion criteria. Here, chromosomal abnormalities
refer to clinically relevant CNVs identified by karyotype and
to recurrent CNVs such as 16p11.2 deletions and duplica-
tions independently reported to AGRE by investigators.
Subjects with evidence for de novo missense SNVs (n = 5
cases) [9] were not excluded, due to the current uncertainty
in determining the effects of missense variation on ASD
risk. In instances of monozygotic multiples, only one
proband was selected at random for inclusion. Subjects
in the AGRE cohort include individuals of Caucasian,
African-American, Asian, and Hispanic ancestry as noted
by self-report and multi-dimensional scaling from genotype
data; subjects were not filtered by ancestry, as the genetic
analyses used in this study (non-parametric linkage, TDT)
were family-based and therefore not susceptible to the
introduction of false positive results from population
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ethnicities may introduce or exacerbate locus hetero-
geneity, which is unlikely to falsely inflate logarithm of
odds (LOD) scores, but instead may reduce power in
linkage studies [32].
Subjects were genotyped in two stages, using DNA puri-
fied from lymphoblastoid cell lines and obtained from the
Rutgers University Cell and DNA Repository (Piscataway,
NJ, USA). Stage 1 consisted of individuals from 1,191
AGRE families, with subjects from 941 families genotyped
on the Illumina 550K genome-wide SNP array as de-
scribed previously [35], and individuals from an additional
250 AGRE families typed on the Illumina Omni-1 Quad
array (Illumina, San Diego, CA, USA) in the University of
California, Los Angeles, Neuroscience Genomics Core.
Stage 2 consisted of individuals from an additional 396
AGRE families, 116 of which were genotyped on the
Illumina Omni-1 array, and 280 of which were typed on
the Illumina Omni-2.5 array (Additional file 1: Table S1).
In total, the combined sample of stage 1 plus stage 2
was comprised of individuals from 1,587 families, 1,008
of which were multiplex and met inclusion criteria as
described above.
Recorded sample identity and pedigree relationships
were validated by evaluating estimations of identical by
descent allele sharing across the genome within and
between families using PLINK software [36]. In cases
with evidence of identity swaps, where available, geno-
type data from the Broad Institute (Affymetrix 5.0
[33]) and the Autism Genome Project (Illumina 1M
[37,38]) were compared to make a final determination
of identity. Subjects and SNPs with >5% missing data were
excluded, and SNPs with Hardy-Weinberg equilibrium
P-values <0.0000001, minor allele frequency <0.01, and >10
Mendelian errors were also excluded. Filtered data sets
from the two stage 1 genotyping platforms were then
merged using PLINK to generate a stage 1 sample data
set with all remaining subjects and the union of marker
sets from the 550K and Omni-1 platforms for a total of
1,092,577 SNPs. To incorporate stage 2 and build the
combined sample data set of all genotyped AGRE subjects,
the union of filtered data from all genotyping platforms
(550K, Omni-1, Omni-2.5) were merged using PLINK for
a total of 1,684,432 SNPs.
Linkage analyses using all families
Autosomal and X chromosome markers common to all
platforms and pruned to a linkage disequilibrium r2 ≤ 0.1
with PLINK were used for genome-wide linkage analysis
(stage 1 data: 57,929 SNPs; combined stage data: 53,648
SNPs). These sets of independent SNPs were mapped to
genetic positions using Rutgers Combined Linkage-Physical
maps [39,40] for linkage testing. Non-parametric, multi-
point linkage was performed genome-wide on all stage 1multiplex families meeting inclusion criteria (n = 847 fam-
ilies) using Merlin (autosomes) and Minx (X chromosome,
executable option within Merlin) [41], which applies the
Kong and Cox linear model [42] to test for small increases
in allele sharing across a large sample of families.
Linked regions identified in the stage 1 sample or by
previous reports (discovery samples) from non-parametric
linkage analyses of AGRE samples using the “broad” af-
fection status criteria were then identified for further
evaluation by defining the 2-LOD interval surrounding
suggestive (LOD ≥2.2) and significant (LOD ≥3.6) signals.
Since the precise physical position of linkage peaks may
vary between studies using marker sets of differing density
and information content (see Cantor and colleagues [25]
for an example), this 2-LOD interval is intended to be
inclusive and to encompass any underlying variability
in the location of previous signals. Where there were
discrepancies between the genetic maps from the original
studies and our data, the span of the interval was an-
chored on the current physical position (hg19) of the
peak marker. Linkage signals from the study by Szatmari
and colleagues [32] were reported as Z|r scores, which we
converted to LOD scores by: LOD= Z|r
2 /(2*ln(10)) [42].
Regions with suggestive linkage evidence from stage 1 or
previous reports were tested for linkage in the combined
sample. Regions at which the discovery sample showed
genome-wide significant linkage (LOD ≥3.6) were then
evaluated for replication (P < 0.01) within a 2-LOD inter-
val from the peak LOD by testing only those independent
families not previously evaluated in the corresponding
discovery analysis.
We applied this three-step (1, discovery; 2, extension
and 3, replication) approach according to guidelines for
linkage analyses of complex traits outlined by Lander
and Kruglyak [43]. As preliminary linkage analyses for
complex traits have yielded suggestive signals, extending
sample sizes by adding pedigrees may allow these loci to
reach genome-wide significance. Once a genome-wide
significant signal has been identified, it may then be
tested for independent replication in a new sample.
The platform and stage at which a family was geno-
typed determined whether they were included in the
discovery (stage 1) or the extension (combined stage)
stages (Figure 1).
Sex-stratified linkage
To identify sex-differential ASD risk loci, we stratified
the genotyped, multiplex families into two groups based
on the sex of their affected children: male-only (MO, no
affected daughters), and female-containing (FC, at least
one affected daughter) [28]; the number of affected-
female-only multiplex families enrolled in AGRE is cur-
rently too low to analyze these families as their own
subgroup. In keeping with earlier sex-stratified linkage
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workable sample sizes, all families with two or more
affected members were assigned by this simple criterion
to either the MO or FC subset, irrespective of the total
affected family members or the presence of unaffected
siblings of the opposite sex. While it can be argued that
MO families with three or more affected brothers or
with at least one unaffected sister are more likely to
carry truly male-specific risk variants (not penetrant in
females) than MO families with fewer affected brothers
or no unaffected sisters, the number of available AGRE
families fitting these criteria is quite low. Specifically, 52
MO families include three or more affected brothers,
and 150 MO families have recorded unaffected sisters.
To avoid further restricting the sample size of our subsets,
we define the MO and FC subsets simply by the sex of the
two or more affected siblings, under the assumption that
the MO and FC subsets are enriched for male-specific and
female-affecting risk variants, respectively, as compared
with the full, non-stratified sample. By this definition, the
stage 1 sample consisted of 487 MO (61%) and 314 FC
(39%) families, and the combined sample consisted of 602
MO (60%) and 406 FC (40%) families (Additional file 1:
Table S1).
Linkage analyses were performed separately in the two
subgroups in three steps as described above for the non-
stratified sample: 1) genome-wide non-parametric link-
age analysis of MO and FC subgroups from the stage 1
sample; 2) regional linkage analysis within suggestive
(LOD ≥2.2) MO- or FC-specific linkage peaks from
discovery studies [25,28] using the corresponding MO
or FC subgroup from the combined sample; and 3) regional
linkage analysis within peaks of genome-wide significant
LOD (≥3.6) in the independent portion of the correspond-
ing MO or FC subgroup from the combined sample who
were not previously tested in the discovery study.
Additionally, to assess the statistical significance of
sex-differential linkage signals, a randomization test of
10,000 subsets of 487 families (matching stage 1 MO
family N) and 314 (stage 1 FC family N) were analyzed
for linkage across chromosomes 1, 4, 6, and 8, where
subgroup-specific suggestive linkage peaks (LOD ≥2.2)
were observed. For the combined sample, random subsets
of 602 (MO family N) were analyzed across chromosome
1, the only chromosome on which a sex-differential signal
surpassed LOD 2.2 in the combined sample. On a
marker-by-marker basis, the LOD score from each of the
10,000 random trials was compared to the results from the
corresponding original, subset-specific scan, and the frac-
tion of random trials for which LODrandom > LODoriginal
was taken as the empirical P-value for stratification,
reflecting the frequency with which the observed LOD
magnitude would occur under the null hypothesis of
no linkage.Imputation
To further improve genotype coverage within linked
regions for fine-scale association testing, imputation
was performed separately by data set, as defined by geno-
typing platform and data collection stage, using IMPUTE2
[44] and a cosmopolitan reference panel from the 1000
Genomes Project [45]. Imputed SNPs from each data set
were then merged using GTOOL [46], and SNPTEST [46]
was used to generate summary statistics for the merged
set. Data were filtered to SNPs with an IMPUTE2 quality
score ≥0.5, missing data in ≤5% of subjects, minor allele
frequency ≥1%, and Hardy Weinberg P ≥ 0.0000001. The
final data set included 5,814,564 autosomal SNPs.Linkage-directed association testing
Imputed SNPs within the 2-LOD intervals surround-
ing linkage peaks exceeding the suggestive threshold
(LOD ≥2.2) in either the stage 1 or combined sample
were tested for association with ASD affection status
in the family group corresponding to the linkage peak
(all families (ALL), MO, or FC) using a TDT with adaptive
gene-dropping permutations (PLINK). Gene dropping
assignments are applied consistently across siblings to
control for linkage and appropriately treat trios from
multiplex families as non-independent [36].
In regions of MO or FC linkage signal, extended families
without multiple affected siblings, but instead with multiple
affected cousins, were additionally included in the associ-
ation analysis (total MO n = 606, including 4 additional
extended families; total FC n = 407, including 1 additional
extended family). In regions of linkage signal from ALL,
an additional 5 extended families and 508 families with
only one genotyped, affected individual were included in
the association analysis (total ALL n = 1,521 families). All
additional families met inclusion criteria as described pre-
viously. Association P-values were adjusted for multiple
testing according to the number of independent SNPs
within each region, as defined by a pairwise linkage
disequilibrium r2 < 0.3 (PLINK).Results
By testing the largest available, uniformly ascertained
ASD family sample (n = 1,008 multiplex families) for
linkage, we aimed to identify novel ASD risk loci not
identified by the previous, smaller analyses of AGRE
samples, and/or to confirm the loci reported by these
analyses. As genotype data were collected in two stages,
we use the stage 1 sample to identify linked and sex-
differential risk loci genome-wide, and the combined
sample (union of stages 1 and 2) to evaluate identified
loci from stage 1 and earlier reports (discovery studies) for
confirmation of linkage in the largest available AGRE
genotype data set.
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Non-parametric, genome-wide linkage analysis for ASD af-
fection status in all stage 1 multiplex families (n = 847) iden-
tified four genomic regions with a peak LOD score ≥2.2
(Table 1, Figure 2), the threshold for suggestive linkage for
a complex trait when allele sharing is tested in sibling pairs
[43]. We observed the highest LOD score at chromosome
6q27, with LODALL.St1 = 3.22 at rs4708676 (190.611 cM).
A 2-LOD interval from this peak SNP spans 18.2 Mb,
31.6 cM, and 100 RefSeq genes (Additional file 2:
Figure S1A), and the peak SNP is 75 kb upstream from
gene FRMD1 [GenBank:NM_024919] (0.4-LOD drop
from peak), a gene with a role in immune function and
significantly associated with IL-2 secretion [47]. All other
linkage regions yielded peak LOD ≥2.2 and are located at
chromosomes 4q13.1 (LODALL.St1 = 2.3), 8p21.2 (LODALL.
St1 = 2.55), and 8q13.2 (LODALL.St1 = 2.5).Table 1 Summary of significant and suggestive linkage peaks
Discovery sample
Source Number
of families
Subgroup Locus*
Liu et al. (2001) [26] 110 ALL 5p13.1
110 ALL Xq26.1
Yonan et al. (2003) [34] 345 ALL 5p13.1
345 ALL 11p13-11.2
345 ALL 17q11.2
Stone et al. (2004) [28] 148 MO 17q11
109 FC 4q32.3-35.1
Cantor et al. (2005) [25] 196 MO 17q21
McCauley et al. (2005) [27] 158 (85 AGRE) ALL 3p25.3
Szatmari et al. (2007) [32] 741 (211 AGRE) MO 5q12
741 (211 AGRE) MO 9q33.3
1181 (387 AGRE) ALL 11p12
440 (176 AGRE) FC 11p12
Weiss et al. (2009) [33] 904 (753 AGRE) ALL 6q27
904 (753 AGRE) ALL 20p13
Current study Stage 1 sample 487 MO 1p31.3
847 ALL 4q13.1
487 MO 4q26
847 ALL 6q27
487 MO 6q27
314 FC 8p21.2
847 ALL 8p21.2
314 FC 8p12
847 ALL 8q13.2
*Refer to Additional file 3: Table S2 for locus details, including boundaries and peak
Bold type indicates logarithm of odds (LOD) scores passing genome-wide significa
†LOD scores passing suggestive linkage thresholds of LOD ≥2.2 in the combined sa
families; FC, female-containing; MO, male-only; SNP, single nucleotide polymorphismTo determine if the signals observed in the stage 1
sample and in previous AGRE studies could be improved
or replicated in a larger sample size, we next carried out
an extension study by testing these regions for linkage in
the combined sample of 1,008 multiplex families (union of
stage 1 and stage 2 samples). Non-parametric linkage ana-
lysis of the combined sample within the regions of interest
confirmed three loci above the suggestive threshold of
LOD ≥2.2: 6q27 (LODALL.Com = 2.50; Additional file 2:
Figure S1A), 8q13.2 (LODALL.Com = 2.82; Additional file 2:
Figure S1B), and 20p13 (LODALL.Com = 3.02; Figure 3). Of
these three loci, only the signal at 8q13.2 increased in the
combined sample. Combined sample linkage on other
chromosomes of interest is shown in Figure 4.
The strongest signal that we observed from the com-
bined sample, and the only signal that surpassed a LOD
score of 3.0, is at 20p13. This locus had been identifiedfrom AGRE samples
Combined sample (Stage 1 + Stage 2)
Peak LOD Number
of families
Peak LOD Peak P-value Peak SNP
2.55 1008 0.99 0.0163 rs6884342
2.56 1008 1.12 0.0116 rs12557711
2.54 1008 0.99 0.0163 rs6884342
2.24 1008 0.92 0.0199 rs2984699
2.83 1008 0.53 0.0592 rs1382779
4.3 602 0.42 0.0834 rs4795708
2.7 406 1.10 0.0121 rs1717072
3.6 602 0.47 0.0706 rs1877032
2.22 1008 0.04 0.3344 rs1400207
2.31 602 1.42 5.34e-3 rs706725
2.36 602 1.47 4.64e-3 rs204169
2.77 1008 0.92 0.0199 rs2984699
2.86 406 0.38 0.0925 rs404977
2.94 1008 2.50† 3.43e-4 rs6931082
3.81 1008 3.02† 9.55e-5 rs6139007
2.98 602 2.55† 3.05e-4 rs7521242
2.30 1008 2.14 8.37e-4 rs1483288
2.41 602 1.28 7.60e-3 rs2196712
3.22 1008 2.50† 3.43e-4 rs6931082
2.86 602 2.07 1.02e-3 rs960145
2.67 406 1.42 5.25e-3 rs7001120
2.55 1008 2.18 7.60e-4 rs13257637
2.37 406 1.34 6.51e-3 rs2976525
2.50 1008 2.82† 1.58e-4 rs4738003
markers.
nce thresholds of LOD ≥3.6 for discovery studies,
mple extension study. AGRE, Autism Genetics Resource Exchange; ALL, all
.
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Figure 2 Genome-wide linkage: stage 1 sample. Logarithm of odds (LOD) scores from genome-wide, non-parametric, multipoint linkage
analysis for autism spectrum disorder affection status in the stage 1 sample are plotted for autosomes (Merlin) and chromosome X (Minx). Top
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http://www.molecularautism.com/content/5/1/13previously in a study that combined 753 AGRE families
with other families from the National Institute of Mental
Health repository [33]. Since 665 of the families in that
analysis overlapped with the current sample, we formally
tested for replication of this locus by analyzing only
those families unique to our study (n = 343 multiplex
families) [33]. We identified a linkage peak within the
20p13 region of interest with a P-value of 0.0076 at
rs214828, thus meeting the significance threshold for
independent replication of linkage for a complex trait
(P < 0.01) [43]. An additional five nearby SNPs also had
P-values of less than 0.01 in this independent family
set. From the peak LODALL.Com of 3.02 at SNP rs6139007
(1.613 cM) in the combined sample, a 2-LOD drop sup-
port interval at this locus spans 4.8 Mb, 14.2 cM, and 87
RefSeq genes (Figure 3). The combined sample peak SNP
is located just 500 bp upstream from the transcription
start site of TRIB3 [GenBank:NM_021158] (0.1-LOD
drop from peak), which encodes a regulator of AKT1
[GenBank:NG_012188] and is expressed mainly in pan-
creas, bone marrow, and leukocytes [48,49]. The inde-
pendent sample peak SNP, rs214828 at 8.403 cM, is
intronic to gene TGM3 [GenBank:NM_003245] (0-LOD
drop from peak), which encodes a calcium-dependent
peptide cross-linking enzyme [50].
While signals at 6q27 and 8q13.2 did not achieve
genome-wide significance in either stage of analysis, the
consistency of the signal at these loci across the discovery
and combined samples suggests these regions may harbor
ASD risk variants; each encompasses promising candidate
genes, including SULF1 [GenBank:NM_001128206] (0-LOD
drop from peak at 8q13.2, Additional file 2: Figure S1B)located directly under the 8q13.2 linkage peak and whose
protein product interacts with growth factors and cy-
tokines in cell signaling [51], and PARK2 [GenBank:
NG_008289] and RPS6KA2 [GenBank:NM_021135] (1.7-
and 0.6-LOD drop, respectively, from peak at 6q27,
Additional file 2: Figure S1A), which are both located
within rare CNVs identified in ASD cases [52-54].
Sex-stratified linkage
To identify sex-differential ASD risk loci, we analyzed
the multiplex families in two separate groups according
to the sex of the affected children in each family: MO
and FC (see Methods) [28]. This sex stratification approach
has been applied only twice in earlier analyses of exclusively
AGRE families, in subgroups only one-third as large as
our stage 1 MO and FC subgroups [25,28]. These earlier
analyses identified and replicated a genome-wide signifi-
cant signal at 17q11-q21 in the MO subgroup, which has
not been subsequently replicated in larger studies [32].
Using our larger sample, we aimed to identify additional
sex-differential risk loci from both the MO and FC
subgroups.
Separate non-parametric, genome-wide linkage analyses
for ASD affection status in the stage 1 MO (n = 487
families) and FC (n = 314 families) subgroups identified
five loci with LOD scores ≥2.2 (Table 2, Figure 2), two
of which overlap peaks from all families (6q27, 8p21.2)
and three that are suggestive only in either the MO or
FC subgroup (1p31.3, 4q26, 8p12).
We observed the highest LOD score for the MO sub-
set at chromosome 1p31.3, with LODMO.St1 = 2.98 at
rs7521242 (92.905 cM); a 2-LOD interval from this peak
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http://www.molecularautism.com/content/5/1/13SNP spans 10.0 Mb, 13.7 cM, and 48 RefSeq genes. Ana-
lysis of this locus in the MO subgroup from the combined
sample identified a smaller, but still suggestive, peak
LODMO.Com = 2.55 also at rs7521242 (Figure 5A). In both
samples, this MO-specific peak is centered on gene NFIA
[GenBank:NG_011787] (0-LOD drop from peak), which is
expressed in the central nervous system and plays a sig-
nificant role in glial cell fate determination and in normal
development of the corpus callosum [55,56]. Exome
sequencing has also identified a de novo, non-synonymous,
loss of function SNV in an autistic subject in this gene,
although the SNV carrier is female [7].
From the FC stage 1 subset, we observed the highest
LOD score at chromosome 8p21.2, with LODFC.St1 =
2.67 at rs10111167 (46.967 cM); a 2-LOD interval from
this peak SNP spans 6.4 Mb, 9.9 cM, and 73 RefSeq
genes (Figure 5C). This FC-specific peak is centered on
gene EBF2 [GenBank:NG_030344] (0-LOD drop from
peak), which encodes a transcription factor that may act
alongside WNT1 [GenBank:NG_033141] to regulate cellu-
lar differentiation during development [57]. However, LODscores in this region from the combined sample FC sub-
group did not reach the suggestive LOD threshold of 2.2.
Similarly, the other sex subgroup-specific peaks at chro-
mosomes 6q27 (LODMO.St1 = 2.86), 4q26 (LODMO.St1 =
2.41), and 8p12 (LODFC.St1 = 2.37), only exceeded LOD of
2.2 in the stage 1 sample (Table 1, Table 2).
We next sought to calculate the likelihood of observing
the MO and FC signals that surpassed (1p31.3, 4q26,
8p21.2, 8p12) or approached (6q27) the magnitude of the
LOD signal from all families by chance. To assess the sig-
nificance of this signal enrichment in the sex-defined sub-
sets, we performed a randomization test for linkage in
10,000 N-matched subsets of families from the full multi-
plex family cohort. The empirical P-value indicates subset-
specific linkage enrichment (empirical P < 0.05 at peak
SNP) at chromosomes 1p31.3 (MO) in both the stage 1 and
the combined samples, and at 8p21.2 (FC), and 8p12 (FC)
in the stage 1 sample (Table 2, Figure 5). These results sug-
gest that the stratification of cohorts by proband sex can re-
veal sex-differential ASD risk loci. However, only the MO
locus at 1p31.3 was supported in the combined sample.
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families; red and FC, female-containing families). Dashed lines mark LOD thresholds of 2.2 for suggestive and 3.6 for significant linkage.
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Table 2 Sex subset-specific linkage signals
Locus Subgroup Stage 1 sample
peak LOD
Combined sample
peak LOD
Gene at suggestive
linkage peak
Sex-differential linkage
empirical P-value
1p31.3 MO 2.98 ——— NFIA <0.01
MO ——— 2.55 NFIA <0.0005
4q26 MO 2.41 1.28 SYNPO2 NS
6q27 MO 2.86 2.07 MLLT4 NS
8p21.2 FC 2.67 1.42 EBF2 <0.05
8p12 FC 2.37 1.34 NRG1 <0.005
Bold type indicates significant sex-differential linkage signals with empirical P ≤ 0.05. FC, female-containing; LOD, logarithm of odds; MO, male-only; NS, not significant.
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http://www.molecularautism.com/content/5/1/13Aside from the signal identified by Weiss and colleagues
[33] at 20p13 in a non-sex-stratified sample, the only
other locus at which genome-wide significant linkage was
previously observed was in a MO subset at 17q11 [28].
This signal was subsequently replicated in an additional
MO subset of AGRE families [25]. In an attempt to further
replicate the signal at this locus, we tested the 407 MO
families from the combined stage that were not included
in either previous analysis. The most significant linkage
P-value that we observe within the 2-LOD drop interval
from the peak signal observed by Cantor and colleagues
[25] (Additional file 3: Table S2) is 0.1003 at rs2014209;
thus, we do not independently replicate the MO signal
at 17q in this sample.
Linkage-directed association
We next tested for association with common genotyped
and imputed SNPs within the 2-LOD intervals around
each linkage peak with LOD ≥2.2 in the stage 1 or the
combined sample. For regions with suggestive signals
from the MO or FC subsets, association testing was run
on the corresponding subset from the combined stage,
with the addition of families with multiple affected cousins
instead of multiple affected siblings. For regions with
suggestive signals from all multiplex families (ALL), as-
sociation testing was run on all multiplex families from
the combined stage with the addition of 508 families with
only a single genotyped, affected member. While we
observe some clusters of SNPs that approach significance,
we did not identify any SNP that survived multiple testing
correction for the number of independent SNPs within
each region, defined by pairwise LD r2 < 0.3. We highlight
the top association signals here for the sake of interest,
although we emphasize that none pass our correction
for multiple comparisons.
The strongest unadjusted association signal within any
linkage region occurred in the ALL peak on chromosome
4q13.1 at rs115667468 with a P-value of 2.997 × 10-5 (after
regional correction, P = 0.154). This associated SNP is
located 7.8 Mb from the SNP at the linkage peak and is
intronic to gene NPFFR2 [GenBank:NM_004885], and
the minor allele T was found to be under-transmitted toaffected offspring from ALL families (odds ratio = 0.4143).
In contrast, the strongest corrected association signal
occurred in the FC peak on chromosome 8p21.2 at
rs78485638 with a corrected P-value of 0.052 (unadjusted
P = 4.206 × 10-5; Figure 5D). This SNP is located 2.7 Mb
from the SNP at the linkage peak, is intronic to gene
LOXL2 [GenBank:NG_002318], and the minor allele T
was found to be under-transmitted to affected offspring
from FC families (odds ratio = 0.4512).
Discussion
To identify and support genomic loci likely to contain
variants contributing to ASD risk in multiplex families
from the AGRE collection, we performed linkage analyses
in all and sex-stratified subsets of multiplex families
followed by targeted association testing in 1,521 families
(1,008 multiplex) from the AGRE cohort. The strongest
linkage signal that we identified was on chromosome
20p13, which exceeded a LOD score of 3.0 in our combined
sample of 1,008 multiplex families. At 20p13, we also rep-
licated in an independent sample from the same AGRE
cohort a previous report of significant linkage at this locus
[33]. Analyses of sex-defined family subgroups and
randomization testing for signals from these subgroups
identified a locus at chromosome 1p31.3 that showed
significant linkage in the MO subgroup in both the stage 1
and combined samples, and loci at chromosomes 8p21.2
and 8p12 that showed significant linkage in the FC
subgroup only in the stage 1 sample. No genotyped or
imputed common SNPs within any linked region proved
to be significantly associated with ASD, an observation
consistent with a model where the influence of multiple
loci of very small effect size, or of rare variants, contributes
to ASD.
The linkage signal at 20p13 is especially noteworthy as
it was the most significant signal that we observed in
our combined sample with a LODAll.Com of 3.02, and it
also meets the criterion for an independent replication
of genome-wide significant linkage [43]. In addition, as
both this study and the study by Weiss and colleagues
[33] were conducted using the AGRE collection, a sample
that has been uniformly ascertained and evaluated over
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Figure 5 Significant sex-differential linkage peaks. Regions of sex subgroup-specific suggestive linkage (logarithm of odds (LOD) ≥2.2) with
empirically significant signal enrichment from randomization testing are plotted. (A) 1p31.3, MO; top: linkage across full chromosome 1 from all
stage 1 family groups; upper-middle: linkage from all stage 1 (solid lines) and combined sample (dashed lines) family groups and association
signal from transmission disequilibrium test (TDT; black dots, EMP1 is empirical P-value from TDT) in male-only (MO) families across 2-LOD interval
from peak LOD; lower-middle: empirical P-values from test of linkage subgroup specificity (black = stage 1, gray = combined), dotted lines indicate
thresholds corresponding to empirical P-values of 0.05, 0.01, and 0.005; bottom: RefSeq gene alignment in 2-LOD interval. (B) Linkage across full
chromosome 8 from all stage 1 family groups. (C) 8p21.2, female-containing (FC), (D) 8p12, FC; for each, top: linkage from all stage 1 family
groups and TDT association in FC families across 2-LOD interval from peak LOD; middle: empirical P-values from stratification permutation tests;
bottom, RefSeq gene alignment in 2-LOD interval.
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http://www.molecularautism.com/content/5/1/13time, this is a clear replication. A 2-LOD interval from the
combined sample peak spans such potential risk candidate
genes as NRSN2 [GenBank:NM_024958] (0.3-LOD drop
from peak), a gene expressed throughout the cerebral
cortex, thalamus, hypothalamus, and in Purkinje cells
[58], and CSNK2A1 [GenBank:NG_011970] (0.5-LOD
drop from peak), which encodes a protein involved in
the regulation of circadian rhythms [59].
For nearly all linked regions identified in the discovery
samples, including 20p13, LOD scores decreased when
analyzed in the combined sample despite the increased
sample size, consistent with previous observations of
genetic heterogeneity [60-62]. However, it is interesting
to note that those signals that were confirmed or repli-
cated in the combined or independent sample were ini-
tially observed by tests of relatively large discovery
samples. This is because, like association testing, a very
large number of small pedigrees are critical to identify
robust linkage signals [63]. In smaller samples, signal
fluctuations between analyses are caused by extreme
heterogeneity of genetic risk loci for ASD [60,61,64],
such that each analysis identifies different, but potentially
true, risk loci. Since linkage peaks represent deviations
from expected proportions of affected family members
sharing two, one, or zero alleles identical by descent at a
particular locus, linkage analyses for complex traits are
particularly sensitive to the composition of families
included in any one test. If, as projected, there are close to
1,000 risk genes for ASD [12], then the chances that a suf-
ficient proportion of families in current sample sizes share
the same risk locus are low.
We recognize that the power we have to detect linkage
in our analyses is for complete linkage with loci of modest
genetic effects on ASD risk [63], and so it is not surprising
that we do not observe genome-wide significant linkage in
either the stage 1 or extended, combined stage samples,
and that most suggestive signals fail to increase in the
extended sample. However, we emphasize that only now
are we approaching the sample sizes necessary to detect
significant linkage in the face of locus heterogeneity in
cohorts comprised of small pedigrees, and that any possible
reduction of locus heterogeneity (for example, by testing
families ascertained by the same cohort as is done here),
will be key to identify replicable linkage signals.Rational stratification of cohorts into subgroups based
on a shared trait may also facilitate the discovery of risk
loci by increasing the relative homogeneity of specific
genetic risk factor(s) in the subgroup. Here, we stratified
our sample by the sex of the probands within each family
to identify loci with sex-differential relationships with
ASD risk, and found significant risk loci at chromosome
1p31.3 (MO), 8p21.2 (FC), and 8p12 (FC). At 1p31.3 and
8p12, linkage signals from the MO and FC subsets, re-
spectively, were significantly stronger than the signal
from the full, non-stratified cohort, suggesting that this
sex-based stratification approach can indeed reduce the
genetic heterogeneity within each subgroup that would
otherwise obscure signals at these loci.
We note that these loci should not be interpreted as
simply sex-specific. Although we cannot say that the MO
group is perfectly restricted to families who carry solely
male-specific variants and therefore only have, and would
ever have, affected male children, we do assume that the
MO subgroup is substantially enriched for families who
carry risk variants that are more penetrant in males. Thus,
signals specific to the MO subset are more likely to be
male-specific. In contrast, since the FC group includes
affected brothers of autistic girls, FC signals are best
interpreted not as female-specific, but as female-affecting
risk loci, in accord with a hypothesis that only a subset of
ASD risk loci are penetrant in females [7,9-13,65].
The significant MO and FC signals identified here impli-
cate regions containing promising candidate genes that
warrant further exploration by targeted re-sequencing
(for example, [66-69]). The MO peak at 1p31.3 is located
directly over NFIA [GenBank:NG_011787], whose gene
product has transcription factor activity and has been
implicated in central nervous system development [55,56].
Rare deletions encompassing this gene have been identified
in subjects with ASD [70], as well as de novo mutations [7].
The FC peak at 8p21.2 spans several candidates, including
STC1 [GenBank:NG_029711] (1.1-LOD drop from peak),
which encodes a glycoprotein regulated by calcium
that may act to protect neurons from ischemia and
hypoxia [71], and neurofilament genes NEFM [GenBank:
NG_008388] and NEFL [GenBank:NG_008492] (both 1.1-
LOD drop from peak) whose products likely function in
transport to neuronal projections [72]. Potentially relevant
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http://www.molecularautism.com/content/5/1/13to sex-differential risk, GNRH1 [GenBank:NG_016457]
(0.7-LOD drop from peak) is also located within this link-
age region, and mutations in this gene are likely to affect
gonadal function [73], perhaps differentially modulating
downstream manifestation of ASD risk factors in males
and females. The neighboring FC peak at chromosome
8p12 is located directly over NRG1 [GenBank:NG_012005]
(0-LOD drop from peak), a known schizophrenia risk
gene [74,75].
A similar stratification approach for the identification
of male-specific and female-affecting ASD risk loci has
been successfully applied previously by Stone and col-
leagues [28] to an early iteration of the AGRE cohort,
as well as by Szatmari and colleagues [32] to a sample
that included a subset of AGRE families, and Lamb and
colleagues [30] and Schellenberg and colleagues [29] to
other ASD family samples. No convergence in linkage
signals was observed across these studies. We predicted
that our ability to identify novel, sex-differential ASD risk
loci in the present study would be aided by a greater than
three-fold increase in subjects exclusively from AGRE as
compared to those used by Stone and colleagues [28] and
by the increase in coverage afforded by dense SNP data in
lieu of several hundred microsatellite markers. However,
the results from our sex-stratified analyses do not reach
genome-wide significance and also do not align with
findings from earlier sex stratification analyses, including
Stone and colleagues [28] who reported a linkage peak at
17q11-q21 in MO families that was subsequently replicated
[25]. This variability between studies is again consistent
with extreme risk locus heterogeneity in ASD [76,77], with
each analysis of a different combination of ASD families
identifying different linked regions.
Under the assumption of genetic heterogeneity, for
complex traits such as ASD, it is possible that the various
loci identified by analyses of different family sets flag true
sites for ASD risk in a proportion of the families tested.
To pursue this, linked loci will need to be investigated
more closely to identify the precise variants that effectively
increase ASD risk. This has so far proven challenging, as
association testing of densely mapped common SNPs
within linkage peaks has failed to definitively identify
risk variants, both in the present study and in previous
work [33].
Although our analyses are likely underpowered to
identify regionally significant associations with common
variants of small effect size, it is alternatively possible that
rare variants, not explicitly tested here, contribute to the
heritable component of ASD risk. For example, rare vari-
ants, shared between siblings but private to each nuclear
family, may cluster in the same gene or set of genes. Since
rare variants are less likely to be tagged by common SNPs,
they should be more readily localized by allele-agnostic
linkage analyses than association testing. As in genediscovery studies of sporadic ASD cases, sequencing of
functional genomic features in linked regions will be
necessary to identify rare variants and evaluate their role
in familial ASD risk. In either case, larger family-based
cohorts will be needed to improve power.
Conclusions
We conclude that the use of linkage analyses in multiplex
family cohorts has complementary utility to genome-wide
association studies for the investigation of the familial,
inherited contribution to ASD risk. This is especially the
case in the context of rare variants in human disease (for
example, [78,79]). Additionally, the use of a sex stratifi-
cation approach facilitates the identification of risk loci
that are differentially associated with ASD in families
with autistic sons versus daughters. However, further
work is needed to determine which gene(s) or genetic
features within linked regions, especially at chromosome
20p13, replicated here, harbor the variants responsible for
increasing familial and sex-differential genetic risk for ASD.
Exploring this in detail via targeted sequencing in large
cohorts will be necessary to elucidate the common versus
rare genetic contributions to ASD.
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